Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $10.00

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned a consensus rating of “Hold” from the nine analysts that are presently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $10.00.

A number of equities research analysts have recently issued reports on the stock. Guggenheim reduced their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th.

Zentalis Pharmaceuticals Stock Down 4.6 %

Shares of NASDAQ:ZNTL opened at $2.92 on Tuesday. Zentalis Pharmaceuticals has a 52 week low of $2.66 and a 52 week high of $18.07. The company has a 50-day moving average price of $3.34 and a 200 day moving average price of $3.64. The company has a market cap of $208.09 million, a P/E ratio of -1.17 and a beta of 1.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. Analysts expect that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP boosted its position in shares of Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after buying an additional 353,384 shares during the period. Decheng Capital LLC grew its position in Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Zentalis Pharmaceuticals by 1,581.9% during the second quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock valued at $730,000 after purchasing an additional 167,854 shares during the period. Verition Fund Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Zentalis Pharmaceuticals by 152.6% during the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after purchasing an additional 399,745 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.